Form 4: Vertex Pharmaceuticals Executive Sells Shares

Vertex Pharmaceuticals EVP, Chief Scientific Officer Mark E. Bunnage reported a sale of common stock executed under a pre-arranged trading plan.

Summary

• Mark E. Bunnage, EVP, Chief Scientific Officer of Vertex Pharmaceuticals, sold 33 shares of common stock on May 15, 2026.
• The transaction was executed at a price of $453.45 per share.
• This sale was made pursuant to a company-approved trading plan under Rule 10b5-1, established on November 26, 2025.
• Following the transaction, Mr. Bunnage beneficially owns 7,284 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the stock sale was conducted under a pre-established trading plan, indicating it's likely part of routine financial management rather than a signal of negative company performance.

Negatives

• An executive of Vertex Pharmaceuticals sold company stock.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an executive.

Industry Context

StockSavvy.ai notes that insider stock sales, particularly when conducted under a Rule 10b5-1 plan, are common and often reflect personal financial planning rather than a negative view of the company's prospects. However, any executive sale can be a point of observation for investors.

Stakeholder Impact

• Shareholders: The sale of 33 shares by an executive may be observed, but is unlikely to have a significant impact given the pre-arranged nature of the trade and the relatively small number of shares sold compared to the executive's total holdings.

Key Dates

Keywords

Vertex Pharmaceuticals, Form 4, Insider Trading, Stock Sale, Mark E. Bunnage, Rule 10b5-1, Common Stock, Executive Officer